LOGIN
Combination therapy improves site-specific BMD vs. teriparatide & denosumab monotherapies
January 2017
Combination therapy improves site-specific BMD vs. teriparatide & denosumab monotherapies
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial
J Clin Densitom. 2016 Jul-Sep;19(3):346-51Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
94 postmenopausal osteoporotic women were randomized to receive either 60mg denosumab subcutaneously every 6 months, 20ug teriparatide subcutaneously daily, or a combination treatment of both 60mg denosumab and 20ug teriparatide for a duration of 24 months. The purpose of this study was to compare the individual response rates of the three treatment groups in terms of increases in bone mineral den...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.